Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Androgen receptor (AR) is a key driver in prostate cancer progression.
• AR signaling is crucial in both hormone-sensitive and hormone-refractory prostate cancer.
• Targeting AR-DNA interactions presents a potential therapeutic strategy.

Purpose of the Study:

• To investigate a DNA-binding polyamide targeting the androgen response element.
• To evaluate the inhibition of AR-regulated gene expression, including prostate-specific antigen (PSA).
• To assess the potential of direct AR-DNA interface inhibition as a therapeutic approach.

Main Methods:

• Utilized a DNA-binding polyamide targeting the consensus androgen response element.
• Assessed inhibition of PSA promoter and other AR-regulated genes in cultured prostate cancer cells.
• Analyzed AR occupancy at the PSA promoter and enhancer.
• Performed genome-wide expression analysis to compare polyamide and bicalutamide effects.

Main Results:

• The polyamide successfully bound the PSA promoter's androgen response element.
• Androgen-induced expression of PSA and other AR-regulated genes was inhibited.
• AR occupancy at the PSA promoter and enhancer was reduced.
• Polyamide treatment showed comparable PSA down-regulation to bicalutamide and affected a similar number of transcripts.

Conclusions:

• Sequence-specific DNA-binding small molecules can directly inhibit the AR-DNA interface.
• This mechanism offers a novel alternative to conventional anti-androgen therapies.
• The developed polyamide demonstrates potential as a new therapeutic agent for prostate cancer.